Dynavax Technologies
$11.15
106
-$0.11-0.94% Friday 16:04
Statistik
Harga Tertinggi Hari
11.22
Harga Terendah Hari
11.15
52M Tertinggi
15.15
52M Terendah
9.5
Volum
92
Volum Purata
1,118
Kapasiti Pasaran
23.22B
Nisbah P/E
0.15
Pendapatan Dividen
-
Dividen
-
Akan Datang
Pendapatan
31OctDijangka
EPS yang dijangka
0.11828
EPS sebenar
N/A
Orang Lain Juga Mengikuti
Senarai ini berdasarkan senarai pantau orang di Stock Events yang mengikuti 0IDA.LSE. Ini bukan cadangan pelaburan.
Peserta
Senarai ini adalah analisis berdasarkan peristiwa pasaran terkini. Ini bukan cadangan pelaburan.
Novavax
NVAX
Kapasiti Pasaran1.98B
Moderna
MRNA
Kapasiti Pasaran29.75B
Pfizer
PFE
Kapasiti Pasaran164.39B
Johnson & Johnson
JNJ
Kapasiti Pasaran399.26B
GSK
GSK
Kapasiti Pasaran89.55B
Sanofi
SNY
Kapasiti Pasaran141.43B
Astrazeneca
AZN
Kapasiti Pasaran271.67B
BioNTech
BNTX
Kapasiti Pasaran20.98B
CureVac N.V.
CVAC
Kapasiti Pasaran704.35M
Mengenai
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.
Show more...
CEO
Mr. Ryan Spencer
Pekerja
408
Negara
US
ISIN
US2681582019